logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Regenxbio: Promising Results from RGX-121 Gene Therapy for Mucopolysaccharidosis Type II (MPS II)

Regenxbio Results from RGX-121 for MPSII Regenxbio ( RGNX ) announced interim data from Phase I/II trial of RGX-121 for Mucopolysaccharidosis Type II ( MPS II) . RGX-121  is designed to deliver the gene that encodes iduronate-2-sulfatase ( I2S )...

Read More

December 19, 2019

0

Why We Decided Not To Abandon the Amgen and Illumina Band Wagons

Amgen Contrary to our expectations   Amgen’s ( AMGN ) shares declined more than 10% in 2019, instead of rallying . Part of the decline followed the threat of devastating the large drug creators and developers by lowering the high...

Read More

July 30, 2019

0

About PTC Therapeutics’ Acquisition of Agilis Biotherapeutics

Yesterday’s news unveiled that PTC Therapeutics (PTCT) has entered into an agreement to acquire   Agilis Biotherapeutics . The transaction was approved by the Boards of both companies. The acquisition Agilis Biotherapeutics is expected to bring to PTC Therapeutics an...

Read More

July 20, 2018

0

The Nektar Good News Cannot be Hidden Any Longer

Nektar Therapeutics We believe that Nektar Therapeutics ( NKTR )  is undervalued. We base this on the firm’s technological capability. Its current pipeline is filled with promising products. Today we learned that the U.S. FDA granted Nektar’s and Bristol-Myers Squibb’s ( BMY...

Read More

August 1, 2019

0

Biogen’s Exciting Q2 Results Highlighted Ionis (IONS) Too

The good news from Biogen’s (BIIB) Q2 exciting financial results comprised impressive news for Ionis (IONS) from the commercialization of Ionis’ approved product, Spinraza for Spinal muscular atrophy (SMA).   Biogen is also responsible for the commercialization of Ionis’ products...

Read More

July 24, 2018

0

More fom the Prohost Portfolio

More from the Prohost Portfolio with Our Observations Gilead ( GILD ) has cash and new products reaching the market, and its agreement with Galapagos will soon bring another drug approval. We will tackle Gilead’s news and all the firms...

Read More

December 20, 2019

0

The FDA approved Neurocrine’s & AbbVie’s Endometriosis drug, Orilissa. Neurocrine stock met & surpassed the Prohost 2018 target

AbbVie (NYSE: ABBV) , in cooperation with Neurocrine Biosciences (NBIX) , announced that the United States FDA approved Orilissa ™ (elagolix) under priority review for women with moderate to severe endometriosis pain. Orilissa represents the first FDA-approved oral treatment for...

Read More

July 25, 2018

0

An Important Statement to Prohost Readers

Prohost has just finished a very hard task; evaluating its best picks from the biotechnology and biopharmaceutical sectors. In this evaluation of hand-selected stocks, Prohost did not consider the negotiation between the U.S. and China a serious factor that could...

Read More

August 5, 2019

0

What We Learned from Yesterday's and Today's Stocks' Moves

What Have We Learned from the Market's Recent Stock Moves? Well. Did we learn anything from what happened in the stock market and the reversal that started near the end of yesterday and occurred today? Listening to Larry Kudlow, the...

Read More

August 6, 2019

0

Exelixis: Why Q2 results are more than impressive

Exciting are the Q2 2018 reported results by Exelixis’ (EXEL) including the firm’s revenues and earnings , compared to 2017. Impressive were Cabometyx’ (cabozantinib) revenues, in addition to the milestone payments from collaborating companies and ex-USA marketing agent. Inspiring also...

Read More

August 2, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 78
  • 79
  • 80
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy